Trials / Completed
CompletedNCT03862716
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (REMIT IDegLira): A Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Population Health Research Institute · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.
Detailed description
This is a multicentre, open-label, randomized controlled trial in 160 patients with recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 16-week course of treatment with IDegLira, metformin and lifestyle therapy, and (b) standard diabetes therapy, and followed for a total of 68 weeks (1 year and 4 months). In all participants with HbA1C\<7.3% at the 16 week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring. Participants with HbA1C ≥ 7.3% at this visit or who experience hyperglycemia relapse after stopping drugs will receive standard glycemic management as informed by the current Canadian Diabetes Association clinical practice guidelines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDegLira | Dose is titrated to achieve fasting normoglycemia |
| DRUG | insulin degludec | In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia. |
| DRUG | Metformin | Dose is titrated to 2000 mg per day or maximal tolerated dose |
| BEHAVIORAL | Lifestyle Therapy | Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving |
Timeline
- Start date
- 2019-04-23
- Primary completion
- 2022-06-15
- Completion
- 2023-07-31
- First posted
- 2019-03-05
- Last updated
- 2023-10-25
Locations
8 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03862716. Inclusion in this directory is not an endorsement.